Title
Obesity and ADHD: Exploring the role of body composition, BMI polygenic risk score, and reward system genes
Date Issued
01 April 2021
Access level
metadata only access
Resource Type
journal article
Author(s)
Martins-Silva T.
Vaz J.d.S.
Genro J.P.
Hutz M.H.
Mota N.R.
Oliveira I.
Gigante D.P.
Pinheiro R.T.
Vitola E.
Grevet E.
Horta B.L.
Rohde L.A.
Tovo-Rodrigues L.
Universidade Federal de Pelotas
Publisher(s)
Elsevier Ltd
Abstract
The association between obesity and attention-deficit hyperactivity disorder (ADHD) has been extensively reported in the literature. However, the potential mechanisms underlying this association are not completely understood. This study aimed to evaluate the association between body composition and ADHD and explore the possible genetic mechanisms involved. We used data from the 1982 Pelotas (Brazil) Birth Cohort at age 30-year follow-up (N = 3630). We first used logistic regression analysis to test whether body mass index (BMI), fat mass (FM), and fat-free mass (FFM) were associated with ADHD. We further tested the association between BMI polygenic risk score (BMI-PRS) and ADHD and the role of the genes upregulated in the reward system using a gene-set association approach. BMI (odds ratio [OR] = 1.05; 95% confidence interval [CI], 1.00–1.09; p = 0.038) and FM (OR = 1.04; 95% CI, 1.00–1.07; p = 0.043) were associated with ADHD. The BMI-PRS was associated with ADHD (using p-value threshold (PT) = 0.4; OR = 1.65; 95% CI, 1.02–2.65) at a nominal level. In gene-set analysis, the reward system genes were associated with BMI in subjects with a high BMI-PRS score, considering PT = 0.4 (p = 0.014). The results suggest that BMI genetic components, especially those genes related to the reward system, may be involved in this association.
Start page
529
End page
536
Volume
136
Language
English
OCDE Knowledge area
Otros temas de medicina clínica Genética humana
Scopus EID
2-s2.0-85094600989
PubMed ID
Source
Journal of Psychiatric Research
ISSN of the container
00223956
Sponsor(s)
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) – Finance Code 001 . Dr. Nina Roth Mota supported by the European Community's Horizon 2020 Programme ( H2020/2014–2020 ) under grant agreements n° 667302 (CoCA). LAR has been a member of the speakers bureau/advisory board and/or acted as a consultant for Eli-Lilly, Janssen-Cilag, Medice, Novartis and Shire in the last 3 years. He receives authorship royalties from Oxford Press and Artmed. He has also received travel awards from Shire for his participation in the 2018 APA meetings and from Novartis to take part of the 2016 AACAP meeting. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Janssen – Cilag, Novartis, and Shire. The remaining authors declare that they have no conflict of interest.
Sources of information: Directorio de Producción Científica Scopus